
Roberto F Speck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6440586/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunophenotypic characterization of TCR γδT cells and MAIT cells in HIV-infected individuals developing Hodgkin's lymphoma. Infectious Agents and Cancer, 2021, 16, 24.	1.2	3
2	The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy. Cancer Research Communications, 2021, 1, 164-177.	0.7	7
3	In utero Hepatitis B Immunization during Fetal Surgery for Spina Bifida. Fetal Diagnosis and Therapy, 2020, 47, 328-332.	0.6	6
4	Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice. Journal of Virology, 2020, 94, .	1.5	11
5	Polymorphisms of SOCS-1 Are Associated With a Rapid HIV Progression Rate. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 189-195.	0.9	4
6	EBV renders B cells susceptible to HIV-1 in humanized mice. Life Science Alliance, 2020, 3, e202000640.	1.3	22
7	Efficient Human Cytomegalovirus Replication in Primary Endothelial Cells Is SOCS3 Dependent. Intervirology, 2019, 62, 80-89.	1.2	1
8	Reply to Hasenkrug et al., "Different Biological Activities of Specific Interferon Alpha Subtypes― MSphere, 2019, 4, .	1.3	4
9	Optimizing Synthetic miRNA Minigene Architecture for Efficient miRNA Hairpin Concatenation and Multi-target Gene Knockdown. Molecular Therapy - Nucleic Acids, 2019, 14, 351-363.	2.3	11
10	Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects. MSphere, 2019, 4, .	1.3	14
11	Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs. Journal of Virology, 2018, 92, .	1.5	29
12	Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART. Virology Journal, 2018, 15, 191.	1.4	11
13	Impairment of CCR6+ and CXCR3+ Th Cell Migration in HIV-1 Infection Is Rescued by Modulating Actin Polymerization. Journal of Immunology, 2017, 198, 184-195.	0.4	21
14	Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV. Journal of Virology, 2017, 91, .	1.5	24
15	Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells. BMC Immunology, 2017, 18, 28.	0.9	55
16	Differential Dynamics of HIV Infection in Humanized MISTRG versus MITRG Mice. ImmunoHorizons, 2017, 1, 162-175.	0.8	9
17	Humanised mouse models for haematopoiesis and infectious diseases. Swiss Medical Weekly, 2017, 147, w14516.	0.8	5
18	Similar efficacy of broad-range ITS PCR and conventional fungal culture for diagnosing fungal infections in non-immunocompromised patients. BMC Microbiology, 2016, 16, 132.	1.3	16

#	Article	IF	CITATIONS
19	Interferon α–Enhanced Clearance of Group A Streptococcus Despite Neutropenia. Journal of Infectious Diseases, 2016, 214, 321-328.	1.9	12
20	Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clinical Infectious Diseases, 2016, 62, 1178-1185.	2.9	59
21	Telomerase Activity Impacts on Epstein-Barr Virus Infection of AGS Cells. PLoS ONE, 2015, 10, e0123645.	1.1	6
22	Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. Journal of Virology, 2015, 89, 6761-6772.	1.5	30
23	Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis. Retrovirology, 2015, 12, 30.	0.9	78
24	Vpx mediated degradation of SAMHD1 has only a very limited effect on lentiviral transduction rate in ex vivo cultured HSPCs. Stem Cell Research, 2015, 15, 271-280.	0.3	10
25	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. PLoS ONE, 2015, 10, e0133879.	1.1	5
26	Activation of NF-κB via Endosomal Toll-Like Receptor 7 (TLR7) or TLR9 Suppresses Murine Herpesvirus 68 Reactivation. Journal of Virology, 2014, 88, 10002-10012.	1.5	22
27	Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infectious Diseases, 2014, 14, 607.	1.3	29
28	Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. Molecular Therapy - Nucleic Acids, 2014, 3, e207.	2.3	17
29	Triggering TLR2, -3, -4, -5, and -8 Reinforces the Restrictive Nature of M1- and M2-Polarized Macrophages to HIV. Journal of Virology, 2014, 88, 9769-9781.	1.5	38
30	Antiretroviral Treatment Testing in HIV-Infected Humanized Mice. , 2014, , 361-380.		2
31	Early gene expression changes by Epsteinâ€Barr virus infection of Bâ€cells indicate CDKs and survivin as therapeutic targets for postâ€transplant lymphoproliferative diseases. International Journal of Cancer, 2013, 133, 2341-2350.	2.3	12
32	Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1. PLoS ONE, 2012, 7, e38853.	1.1	72
33	Modeling HIV infection and therapies in humanized mice. Swiss Medical Weekly, 2012, 142, w13618.	0.8	28
34	Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption. BMJ Case Reports, 2011, 2011, bcr0320113928-bcr0320113928.	0.2	4
35	HIV interferes with SOCSâ€1 and â€3 expression levels driving immune activation. European Journal of Immunology, 2011, 41, 1058-1069.	1.6	28
36	Evaluation of the Immunomodulatory and Antiviral Effects of the Cytokine Combination IFN-α and IL-7 in the Lymphocytic Choriomeningitis Virus and Friend Retrovirus Mouse Infection Models. Viral Immunology, 2011, 24, 375-385.	0.6	6

#	Article	IF	CITATIONS
37	Broad-Range 16S rRNA Gene Polymerase Chain Reaction for Diagnosis of Culture-Negative Bacterial Infections. Clinical Infectious Diseases, 2011, 53, 1245-1251.	2.9	152
38	TLR8 Activates HIV from Latently Infected Cells of Myeloid-Monocytic Origin Directly via the MAPK Pathway and from Latently Infected CD4+ T Cells Indirectly via TNF-α. Journal of Immunology, 2011, 186, 4314-4324.	0.4	47
39	TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene, 2010, 29, 4588-4598.	2.6	26
40	β ₁ Integrin Expression Increases Susceptibility of Memory B Cells to Epstein-Barr Virus Infection. Journal of Virology, 2010, 84, 6667-6677.	1.5	26
41	Recognition of Potentially Novel Human Disease-Associated Pathogens by Implementation of Systematic 16S rRNA Gene Sequencing in the Diagnostic Laboratory. Journal of Clinical Microbiology, 2010, 48, 3397-3402.	1.8	14
42	Short Communication: B Cells from HIV-Infected Patients with Primary Central Nervous System Lymphoma Display an Activated Phenotype and Have a Blunted TNF-α Response to TLR9 Triggering. AIDS Research and Human Retroviruses, 2010, 26, 1063-1074.	0.5	6
43	Low Postseroconversion CD4 Count and Rapid Decrease of CD4 Density Identify HIV ⁺ Fast Progressors. AIDS Research and Human Retroviruses, 2010, 26, 997-1005.	0.5	9
44	Inadequate Clearance of Translocated Bacterial Products in HIV-Infected Humanized Mice. PLoS Pathogens, 2010, 6, e1000867.	2.1	63
45	Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental settingâ ⁻ †. European Journal of Cardio-thoracic Surgery, 2009, 35, 457-462.	0.6	10
46	Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. Seminars in Immunopathology, 2009, 31, 257-266.	2.8	50
47	Plasma cell tollâ€like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology, 2009, 128, 573-579.	2.0	90
48	Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. Aids, 2009, 23, 1918-1922.	1.0	28
49	Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood, 2009, 113, 377-388.	0.6	126
50	RAG2 ^{â^'/â^'} γ _c ^{â^'/â^'} Mice Transplanted with CD34 ⁺ Cells from Human Cord Blood Show Low Levels of Intestinal Engraftment and Are Resistant to Rectal Transmission of Human Immunodeficiency Virus. Journal of Virology, 2008, 82, 12145-12153.	1.5	40
51	Distinct Ex Vivo Susceptibility of B-Cell Subsets to Epstein-Barr Virus Infection According to Differentiation Status and Tissue Origin. Journal of Virology, 2008, 82, 4400-4412.	1.5	26
52	Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5189-5194.	3.3	158
53	Anti-HIV Activity Mediated by Natural Killer and CD8+ Cells after Toll-Like Receptor 7/8 Triggering. PLoS ONE, 2008, 3, e1999.	1.1	34
54	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. Aids, 2007, 21, 441-446.	1.0	139

4

#	Article	IF	CITATIONS
55	Adaptation of the Ultrasensitive HIV-1 p24 Antigen Assay to Dried Blood Spot Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 247-253.	0.9	23
56	Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cellular Microbiology, 2007, 9, 2055-2069.	1.1	30
57	Methadone-induced Torsade de pointes after stopping lopinavir–ritonavir. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 367-369.	1.3	32
58	Disseminated and sustained HIV-infection in CD34+ cord blood cell transplanted Rag2-/-gc-/- mice. Retrovirology, 2006, 3, S31.	0.9	1
59	Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. Journal of Clinical Virology, 2006, 36, 64-67.	1.6	19
60	Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-Âc-/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15951-15956.	3.3	224
61	Anti-HIV State but Not Apoptosis Depends on IFN Signature in CD4+ T Cells. Journal of Immunology, 2006, 177, 6227-6237.	0.4	32
62	TLR7/8 Triggering Exerts Opposing Effects in Acute versus Latent HIV Infection. Journal of Immunology, 2006, 176, 2888-2895.	0.4	110
63	Disseminated and Sustained HIV-Infection in CD34+ Cord Blood Cell Transplanted Rag2â^'/â^'gcâ^'/â^' Mice Blood, 2006, 108, 489-489.	0.6	0
64	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. Aids, 2005, 19, 1987-1994.	1.0	29
65	Rapidly Destructive Staphylococcus epidermidis Endocarditis. Infection, 2005, 33, 148-150.	2.3	16
66	Uncoupled Anti-HIV and Immune-Enhancing Effects when Combining IFN- $\hat{l}\pm$ and IL-7. Journal of Immunology, 2005, 175, 3724-3736.	0.4	12
67	CpG Oligodeoxynucleotides Block Human Immunodeficiency Virus Type 1 Replication in Human Lymphoid Tissue Infected Ex Vivo. Journal of Virology, 2004, 78, 12344-12354.	1.5	42
68	HIV‧pecific Cellular Immune Response Is Inversely Correlated with Disease Progression as Defined by Decline of CD4+T Cells in Relation to HIV RNA Load. Journal of Infectious Diseases, 2004, 189, 1199-1208.	1.9	26
69	HIV-1 Does Not Provoke Alteration of Cytokine Gene Expression in Lymphoid Tissue after Acute Infection Ex Vivo. Journal of Immunology, 2004, 172, 2687-2696.	0.4	22
70	CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis. Clinical and Experimental Immunology, 2004, 137, 566-569.	1.1	9
71	Human tonsillar tissue block cultures differ from autologous tonsillar cell suspension cultures in lymphocyte subset activation and cytokine gene expression. Journal of Immunological Methods, 2004, 289, 179-190.	0.6	17
72	Alveolar Echinococcosis of the Liver in an Adult with Human Immunodeficiency Virus Type-1 Infection. Infection, 2004, 32, 299-302.	2.3	58

#	Article	IF	CITATIONS
73	Impaired CD8+ T-Cell Reactivity against Viral Antigens in Cancer Patients with Solid Tumors. Infection, 2004, 32, 287-292.	2.3	3
74	Anti-HIV-1 activity of leflunomide. Aids, 2003, 17, 1613-1620.	1.0	37
75	Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Aids, 2003, 17, 1613-20.	1.0	22
76	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. Antiviral Therapy, 2003, 8, 443-454.	0.6	23
77	Multifocal Vasculopathy Due to Varicellaâ€Zoster Virus (VZV): Serial Analysis of VZV DNA and Intrathecal Synthesis of VZV Antibody in Cerebrospinal Fluid. Clinical Infectious Diseases, 2002, 35, 330-333.	2.9	23
78	Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1. Journal of Experimental Medicine, 2002, 195, 719-736.	4.2	97
79	Rapid detection of the CCR2-V64I, CCR5-A59029G and SDF1-G801A polymorphisms by tetra-primer PCR. Clinical Biochemistry, 2002, 35, 399-403.	0.8	10
80	Folate Receptor-α Is a Cofactor for Cellular Entry by Marburg and Ebola Viruses. Cell, 2001, 106, 117-126.	13.5	200
81	Susceptibility of Rat-Derived Cells to Replication by Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 8063-8073.	1.5	63
82	Impact of TNFα, LTα, FcγRII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. Aids, 2000, 14, 2661-2669.	1.0	5
83	Molecular Function of the CD4 D1 Domain in Coreceptor-Mediated Entry by HIV Type 1. AIDS Research and Human Retroviruses, 2000, 16, 1845-1854.	0.5	13
84	Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease. Journal of Virology, 2000, 74, 184-192.	1.5	65
85	Human Immunodeficiency Virus Type 1 Coreceptor Preferences Determine Target T-Cell Depletion and Cellular Tropism in Human Lymphoid Tissue. Journal of Virology, 2000, 74, 5347-5351.	1.5	67
86	Distinct Mechanisms of Entry by Envelope Glycoproteins of Marburg and Ebola (Zaire) Viruses. Journal of Virology, 2000, 74, 4933-4937.	1.5	131
87	Human Immunodeficiency Virus Type 1 Coreceptor Preferences Determine Target T-Cell Depletion and Cellular Tropism in Human Lymphoid Tissue. Journal of Virology, 2000, 74, 5347-5351.	1.5	4
88	Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine plus Saquinavir or Zidovudine and Zalcitabine plus Saquinavir in AIDS Clinical Trials Group 229. Journal of Infectious Diseases, 1999, 179, 249-253.	1.9	9
89	A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1. Current Biology, 1999, 9, 547-550.	1.8	57
90	V3 Recombinants Indicate a Central Role for CCR5 as a Coreceptor in Tissue Infection by Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 2350-2358.	1.5	75

#	Article	IF	CITATIONS
91	Rabbit Cells Expressing Human CD4 and Human CCR5 Are Highly Permissive for Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1998, 72, 5728-5734.	1.5	34